Shoshana Shendelman, Applied Therapeutics CEO/founder
Biotech pulls plans to file accelerated approval after FDA 'change in direction' — shares plummet
When the FDA lifted a clinical hold on Applied Therapeutics’ lead program in galactosemia last February, the New York biotech signaled that they were …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
